- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04968574
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
February 21, 2024 updated by: Endeavor Biomedicines, Inc.
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF.
Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment.
Following treatment, subjects will be observed for an additional 6 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Endeavor Clinical Trials
- Phone Number: 1-858-727-3199
- Email: ebmclinical@endeavorbiomedicines.com
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 1871
- Research Site
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- Research Site
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Research Site
-
Clayton, Victoria, Australia, 3168
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Research Site
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Site
-
-
-
-
-
Incheon, Korea, Republic of
- Research Site (Namdong District)
-
Seongnam, Korea, Republic of
- Research Site (Bundang District)
-
Seoul, Korea, Republic of
- Research Site (Gangnam District)
-
Seoul, Korea, Republic of
- Research Site (Seongbuk District)
-
Seoul, Korea, Republic of
- Research Site (Songpa District)
-
-
-
-
-
Batu Caves, Malaysia, 68100
- Research Site
-
Kota Bharu, Malaysia, 15200
- Research Site
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuala Lumpur, Malaysia, 53000
- Research Site
-
Kuala Lumpur, Malaysia, 56000
- Research Sire
-
-
-
-
-
Chihuahua, Mexico, 31203
- Research Site
-
Mexico City, Mexico, 03100
- Research Site
-
Mexico City, Mexico, 14080
- Research Site
-
Oaxaca, Mexico, 68000
- Research Site
-
Puebla, Mexico, 72180
- Research Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64060
- Research Site
-
Monterrey, Nuevo Leon, Mexico, 64718
- Research Site
-
San Nicolás De Los Garza, Nuevo Leon, Mexico, 66465
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- IPF diagnosis based upon American Thoracic Association, Japanese Respiratory Society, European Respiratory Society, Latin American Thoracic Association guidelines within the last 7 years. Diagnosis will be confirmed to be consistent with IPF by centrally read high resolution computed tomography (HRCT).
- Ability to successfully perform lung function tests.
- Subjects are willing to remain on study treatment for the duration of the study.
- Subjects have a full understanding of the informed consent.
Exclusion Criteria:
- Evidence of other known causes of interstitial lung disease (ILD) (e.g., domestic, and occupational environmental exposures, connective tissue disease [CTD], and drug toxicity), lung transplant expected within 12 months of screening or evidence of clinically significant lung disease other than IPF including but not limited to asthma, chronic obstructive pulmonary disease (COPD), uncontrolled pulmonary hypertension and emphysema where computed tomography (CT)-assessed extent of emphysema is greater than extent of fibrosis.
History of malignancy, including carcinoma during the preceding 5 years. With the following exceptions:
- Prior history of in situ basal or squamous cell skin cancer that was successfully treated with curative therapies.
- Subjects with other malignancies if they have been continuously disease free for at least 5 years prior to study start.
- Subjects with prostate cancer that are managed by surveillance are also eligible.
- Current use of supplemental oxygen for any condition unless prior approval is received from the Sponsor.
- Smoking within 6 months of study start, current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
- Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
- Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
Current or previous use (within 30 days prior to study start) of the following:
- N-acetylcysteine
- endothelin receptor antagonist
- riociguat
- prostacyclin or prostacyclin analogue
- Warfarin for IPF
- Cytotoxic agents (e.g., colchicine if used for IPF)
- Radiation to the lungs
- Pulmonary rehabilitation
- Investigational agent for IPF
- Immunosuppressive medications (e.g., methotrexate, azathioprine)
- Systemic or inhaled glucocorticosteroids
- Antifibrotic therapy (e.g., nintedanib, pirfenidone)
- Regular use of phosphodiesterase type-5 inhibitor, occasional use for erectile dysfunction will be allowed.
- Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start.
- Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose.
- Females that are pregnant or nursing.
- Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose.
- Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose.
- Subjects with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ENV-101
taladegib, 200 mg tablet, once daily for 12 weeks
|
hedgehog pathway inhibitor dosed once daily
|
Placebo Comparator: placebo
placebo, tablet, once daily for 12 weeks
|
identical tablets to the experimental arm with no active ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in frequency of adverse events (AEs)
Time Frame: Baseline to Week 18
|
An AE is any untoward medical occurrence in a study subject administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment under investigation.
Frequency of a given AE is determined by dividing the total number of that AE observed during the study by the total number of subjects in the study.
|
Baseline to Week 18
|
Change from baseline in severity of AEs
Time Frame: Baseline to Week 18
|
Severity of AEs are categorized as mild, moderate or severe as described below:
|
Baseline to Week 18
|
Change from baseline in vital sign measurements - pulse
Time Frame: Baseline to Week 18
|
Comparison of a subject's pulse rate at the beginning of the study to that subject's pulse rate at the completion of the study.
|
Baseline to Week 18
|
Change from baseline in vital sign measurements - blood pressure
Time Frame: Baseline to Week 18
|
Comparison of a subject's blood pressure at the beginning of the study to that subject's blood pressure at the completion of the study.
|
Baseline to Week 18
|
Change from baseline in vital sign measurements - respiration rate
Time Frame: Baseline to Week 18
|
Comparison of a subject's respiration rate (number of breaths taken per minute while at rest) at the beginning of the study to that subject's respiration rate at the completion of the study.
|
Baseline to Week 18
|
Change from baseline in vital sign measurements - temperature
Time Frame: Baseline to Week 18
|
Comparison of a subject's body temperature at the beginning of the study to that subject's body temperature at the completion of the study.
|
Baseline to Week 18
|
Change from baseline in blood oxygen saturation level
Time Frame: Baseline to Week 18
|
Comparison of a subject's blood oxygen saturation level (measured at rest using a pulse oximeter) at the beginning of the study to that subject's blood oxygen saturation level at the completion of the study.
|
Baseline to Week 18
|
Incidence of clinical laboratory abnormalities
Time Frame: Baseline to Week 18
|
Assessment of the clinical laboratory measurements (chemistry, hematology, urinalysis parameters) that are above or below the laboratory normal ranges.
Incidence of clinical laboratory abnormalities is determined by dividing the total number of clinical laboratory abnormalities by the total number of subjects in the study.
|
Baseline to Week 18
|
Severity of clinical laboratory abnormalities
Time Frame: Baseline to Week 18
|
Assessment of the severity (defined as either clinically significant or not clinically significant) for the clinical laboratory abnormalities observed during the study.
|
Baseline to Week 18
|
Number of hospitalizations
Time Frame: Baseline to Week 18
|
Assessment of the number of hospitalizations for any reason observed among all subjects from the beginning of the study to the completion of the study.
|
Baseline to Week 18
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of FVC (forced vital capacity)
Time Frame: Baseline and Week 12
|
FVC is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured during a spirometry test.
|
Baseline and Week 12
|
Change from baseline of DLCO (diffusing capacity of the lungs for carbon monoxide)
Time Frame: Baseline and Week 12
|
DLCO is a measurement of the ease of transfer for carbon monoxide molecules from alveolar gas to the hemoglobin of the red blood cells in the pulmonary circulation.
|
Baseline and Week 12
|
Change from baseline of patient reported outcomes by the University of California-San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)
Time Frame: Baseline and Week 12
|
The UCSD SOBQ consists of 24 questions (21 assess severity of shortness of breath during specific activities of daily living; 3 additional items ask about limitations due to: shortness of breath, fear of harm from overexertion and fear of shortness of breath).
Each question has a 6-point scale (0 = "not at all" to 5 = "maximal or unable to do because of breathlessness"), resulting in a total score ranging from 0 to 120 (a higher score represents a worse outcome).
|
Baseline and Week 12
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline of FVC
Time Frame: Baseline and Week 6
|
Baseline and Week 6
|
Change from baseline of FVC
Time Frame: Baseline and Week 18
|
Baseline and Week 18
|
Change from baseline of DLCO
Time Frame: Baseline and Week 6
|
Baseline and Week 6
|
Change from baseline of DLCO
Time Frame: Baseline and Week 18
|
Baseline and Week 18
|
Change from baseline of patient reported outcomes by the UCSD SOBQ
Time Frame: Baseline and Week 6
|
Baseline and Week 6
|
Change from baseline of patient reported outcomes by the UCSD SOBQ
Time Frame: Baseline and Week 18
|
Baseline and Week 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Paul Frohna, M.D., Ph.D., Endeavor Biomedicines
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 26, 2021
Primary Completion (Actual)
November 30, 2023
Study Completion (Actual)
November 30, 2023
Study Registration Dates
First Submitted
June 29, 2021
First Submitted That Met QC Criteria
July 8, 2021
First Posted (Actual)
July 20, 2021
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENV-IPF-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on taladegib
-
Endeavor Biomedicines, Inc.Active, not recruitingSolid Tumors With PTCH1 Loss-of-function MutationsUnited States
-
Endeavor Biomedicines, Inc.CompletedIdiopathic Pulmonary FibrosisAustralia
-
Eli Lilly and CompanyCompletedSoft Tissue Sarcoma | Breast Cancer | Solid Tumor | Cholangiocarcinoma | Colon CancerUnited States, France, Spain, Denmark
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedGastroesophageal Junction Adenocarcinoma | Stage IB Esophageal Adenocarcinoma AJCC v7 | Stage II Esophageal Adenocarcinoma AJCC v7 | Stage IIA Esophageal Adenocarcinoma AJCC v7 | Stage IIB Esophageal Adenocarcinoma AJCC v7 | Stage IIIA Esophageal Adenocarcinoma AJCC v7 | Stage IIIB Esophageal...United States